Group One Trading’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$265K Sell
800
-20,700
-96% -$7.04M ﹤0.01% 3896
2025
Q4
$8.55M Buy
21,500
+3,900
+22% +$1.73M 0.01% 1053
2025
Q3
$8.03M Buy
17,600
+2,100
+14% +$855K 0.01% 1084
2025
Q2
$5.05M Sell
15,500
-12,900
-45% -$3.57M 0.01% 1321
2025
Q1
$7.67M Buy
28,400
+6,900
+32% +$1.77M 0.02% 778
2024
Q4
$5.06M Sell
21,500
-17,000
-44% -$4.47M 0.01% 1160
2024
Q3
$10.6M Buy
38,500
+14,000
+57% +$3.65M 0.03% 594
2024
Q2
$5.95M Sell
24,500
-8,000
-25% -$1.26M 0.02% 703
2024
Q1
$4.86M Sell
32,500
-28,000
-46% -$4.67M 0.02% 846
2023
Q4
$11.6M Sell
60,500
-8,700
-13% -$1.48M 0.03% 620
2023
Q3
$12.3M Buy
69,200
+29,300
+73% +$5.59M 0.04% 416
2023
Q2
$7.58M Sell
39,900
-1,400
-3% -$278K 0.02% 683
2023
Q1
$8.27M Sell
41,300
-1,300
-3% -$273K 0.03% 581
2022
Q4
$10.1M Buy
42,600
+12,600
+42% +$2.69M 0.02% 733
2022
Q3
$6M Sell
30,000
-59,600
-67% -$11.4M 0.01% 1033
2022
Q2
$13.1M Buy
89,600
+69,400
+344% +$9.85M 0.02% 683
2022
Q1
$3.3M Sell
20,200
-24,100
-54% -$3.67M ﹤0.01% 1896
2021
Q4
$7.51M Buy
44,300
+3,900
+10% +$725K 0.01% 1351
2021
Q3
$7.63M Buy
40,400
+19,600
+94% +$3.68M 0.01% 1309
2021
Q2
$3.53M Buy
20,800
+14,500
+230% +$2.12M ﹤0.01% 2038
2021
Q1
$890K Sell
6,300
-36,700
-85% -$5.52M ﹤0.01% 3373
2020
Q4
$5.59M Sell
43,000
-2,100
-5% -$280K 0.01% 1191
2020
Q3
$6.57M Buy
45,100
+23,300
+107% +$3.31M 0.02% 744
2020
Q2
$3.23M Sell
21,800
-38,200
-64% -$5.15M 0.01% 1117
2020
Q1
$6.53M Sell
60,000
-18,200
-23% -$2.1M 0.05% 409
2019
Q4
$9.01M Sell
78,200
-20,600
-21% -$2.05M 0.06% 395
2019
Q3
$7.95M Buy
98,800
+78,300
+382% +$6.19M 0.06% 366
2019
Q2
$1.49M Sell
20,500
-20,200
-50% -$1.55M 0.01% 1317
2019
Q1
$3.8M Sell
40,700
-66,900
-62% -$5.6M 0.04% 566
2018
Q4
$7.84M Sell
107,600
-4,100
-4% -$315K 0.07% 332
2018
Q3
$9.78M Buy
111,700
+33,500
+43% +$3.37M 0.08% 292
2018
Q2
$7.7M Buy
78,200
+61,300
+363% +$6.08M 0.07% 351
2018
Q1
$2.01M Sell
16,900
-8,400
-33% -$1.08M 0.02% 1005
2017
Q4
$3.21M Sell
25,300
-114,800
-82% -$14.4M 0.02% 891
2017
Q3
$16.5M Buy
140,100
+95,100
+211% +$8.12M 0.15% 131
2017
Q2
$3.59M Buy
45,000
+10,800
+32% +$690K 0.04% 627
2017
Q1
$1.75M Sell
34,200
-3,800
-10% -$176K 0.02% 951
2016
Q4
$1.42M Sell
38,000
-33,000
-46% -$1.38M 0.01% 1111
2016
Q3
$4.81M Buy
71,000
+21,000
+42% +$1.48M 0.05% 427
2016
Q2
$2.77M Buy
50,000
+8,600
+21% +$542K 0.03% 637
2016
Q1
$2.6M Buy
41,400
+28,900
+231% +$1.92M 0.04% 631
2015
Q4
$1.18M Buy
12,500
+2,700
+28% +$250K 0.01% 1206
2015
Q3
$788K Buy
9,800
+4,000
+69% +$444K 0.01% 1426
2015
Q2
$695K Sell
5,800
-14,200
-71% -$1.7M 0.01% 1513
2015
Q1
$2.09M Sell
20,000
-8,900
-31% -$902K 0.03% 613
2014
Q4
$2.8M Buy
28,900
+9,000
+45% +$834K 0.04% 479
2014
Q3
$1.55M Buy
19,900
+9,400
+90% +$606K 0.02% 838
2014
Q2
$663K Buy
10,500
+9,400
+855% +$559K 0.01% 1424
2014
Q1
$74K Sell
1,100
-2,700
-71% -$209K ﹤0.01% 3328
2013
Q4
$244K Sell
3,800
-12,200
-76% -$728K ﹤0.01% 2252
2013
Q3
$1.02M Sell
16,000
-25,500
-61% -$1.27M 0.02% 1002
2013
Q2
$1.29M Buy
+41,500
New +$1.1M 0.03% 654

Other funds holding ALNY

Group One Trading's ALNY Position: Q1 2026 in Review

Group One Trading opened a new position in Alnylam Pharmaceuticals (ALNY) in Q1 2026: 5,545 shares worth $1.83M. The stake represents ﹤0.01% of the portfolio and ranks #2148 among its holdings. This is a return to the name: Group One Trading previously reported a position in ALNY as recently as Q2 2025.

Group One Trading first reported a position in ALNY in Q2 2013 and has held it in 29 quarters since. The position peaked at $9.07M in Q2 2022. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Group One Trading held 5,545 shares of Alnylam Pharmaceuticals worth $1.83M as of Q1 2026.
  • Alnylam Pharmaceuticals was a new Group One Trading position in Q1 2026.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Group One Trading's portfolio in Q1 2026, its #2148 holding.
  • Group One Trading first reported a position in Alnylam Pharmaceuticals in Q2 2013 and has held it in 29 quarters since.
  • Group One Trading's Alnylam Pharmaceuticals position peaked at $9.07M in Q2 2022.
  • 786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.